ClinicalTrials.gg
CompletedNCT06433193Updated Apr 1, 2025

Early Feasibility Study to Evaluate the Safety and Efficacy of PAK HD in ESRD Patients

An interventional study of PAK HD Sorbent Therapy in End Stage Renal Disease and ESRD, sponsored by Nextkidney S.A.. Completed at 1 site in Singapore. Open to participants aged 21 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Nextkidney S.A. · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2024, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
21 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Kidney Failure, Chronic with a site in Singapore — 2 open to participants now, 2 under way, none of them phase 3. Kidney Failure, Chronic · Singapore.

Enrollment
16th of 16
3 · median 99
Started
2024
the only one that year
No phase
9 of 17
2 open now
Registered
15th of 17
by date
Lead sponsor
1 of 17
Nextkidney S.A.

Among the 17 studies in Kidney Failure, Chronic with a site in Singapore, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 15th registered.

Kidney Failure, Chronic

2,114 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

2 of the 17 studies in Kidney Failure, Chronic with a site in Singapore are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 21 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Kidney Failure, Chronic with a site in Singapore, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the safety of dialysate regeneration of the PAK HD sorbent cartridge and therapy efficacy of the PAK HD sorbent therapy compared with conventional hemodialysis.

Read the detailed description

This clinical trial is being conducted to evaluate the biochemical safety of dialysate regeneration with the PAK HD sorbent cartridge in a limited number of patients and treatments. Therapy efficacy of the PAK HD sorbent therapy will be compared to conventional hemodialysis under the same therapy settings. The trial will use only one single PAK HD sorbent therapy per patient, and a total of 3 patients. The PAK HD therapies will be performed in the middle of the week.

03

Conditions studied

  • End Stage Renal Disease
  • ESRD
04

Who can participate

Ages eligible
21 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be adults >/= 21 years old and \<80 years old.
  2. Subjects must be weighing >/= 55kg and \<90kg (patient's dry weight).
  3. Subjects must have stable >/= 10.5g/dL, 2 months prior to enrolment
  4. Subjects' pre-dialysis serum values must be within the following range, 2 months prior to enrolment:

    Patient allowable serum biochemistry ranges Allowable pre-dialysis serum values Na >/= 132 mmol/L or \</= 145mmol/L HCO3 >/= 15mmol/L or \</= 30mmol/L K >/= 3.5mmol/L or \</= 5.8mmol/L

  5. Subjects on stable on thrice weekly 4-h HD schedule. Stability is defined as:

    • Haemodynamic stability during dialysis (absence of hypotensive events and symptomatic arrhythmias), no angina pectoris, AND
    • No altered level of consciousness during dialysis.
  6. Subjects with a well-functioning vascular access (native fistula graft):

    • capable of providing a blood flow rate of >/= 250 mL/min, AND
    • no vascular access revision and stable shunt flow for at least 4 weeks prior to enrolment.
  7. Subjects capable of understanding the form and give informed consent.
  8. Subjects willing and able to comply with study procedures and to attend all study follow-up visits.
  9. Subjects who are female of reproducible age to practice methods.
  10. Subjects can be either gender.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with level of \<10.5g/dL in any measurement 2 months prior to enrolment.
  2. Subjects with the following pre-dialysis serum values in any measurement 2 months prior to enrolment:

    • sodium concentration \<132 mmol/L or > 145mmol/L
    • bicarbonate \<15mmol/L or >30mmol/L
    • plasma potassium concentration \<3.5mmol/L or >5.8mmol/L
    • urea \<15mmol/L or >28 mmol/L
  3. Subjects with severe hypertension: systolic blood pressure > /=180 mmHg, diastolic blood pressure >/=120 mmHg in any officemeasurement less than 4 weeks prior to enrolment.
  4. Subjects with or any respiratory disease that may predispose to CO2 retention.
  5. Subjects with impaired liver function. Impaired liver function is defined as an elevated (alanine aminotransferase) by 3-fold orgreater above the .
  6. Subjects with episodes of haemolysis in any measurement 3 months prior to enrolment.
  7. Subjects with a central venous catheter.
  8. Subjects with vascular access dysfunction (whether or not requiring an intervention), i.e. failure to achieve and/ or sustain a bloodflow of >/=250 mL/min and/or signs of compromised vascular access patency (according to the opinion of the investigator) within 4weeks prior to enrolment.
  9. Subjects with vascular access related infection less than 4 weeks prior to enrolment
  10. Subjects requiring an average ultrafiltration volume >2.8 L per 4-h treatment in mid-week dialysis session in the past 4 weeks priorto enrolment.
  11. Subjects who are on heparin free dialysis
  12. Subjects who are unable to provide .
  13. Subjects who are unable to comply with study procedures.
  14. Subjects with psychosocial problems which may negatively influence dialysis treatment.
  15. Subjects who participated in another clinical intervention or device trial less than 12 weeks prior to enrolment, are currentlyparticipating or intend to participate in such a trial.
  16. Subjects who are pregnant, breast feeding, or planning a pregnancy within the study period.
  17. Subjects with a \<1 year.
  18. Subjects who are anticipating a living donor kidney transplantation within \< 2 months of the study period.
  19. Subjects with recent history of drug and/or alcohol abuse in the last 3 months prior to enrolment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    PAK HD Sorbent Study

    The study will be performed as a prospective, non-randomised, single arm two-period cross-over study comparing conventional CHD to PAK HD. All adverse events will be recorded and reviewed. Only one subject will enter each study period at a time.

    Device: PAK HD Sorbent Therapy

Interventions

  • DevicePAK HD Sorbent Therapy

    Study Period 1: Subjects will receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, one 4h CHD therapy will be performed at a dialysate flow rate (QD) of 300mL/min, identical to the dialysate flow rate of the PAK HD sorbent therapy. Blood and dialysate samples will be collected during treatment and sent for analysis, for comparison with PAK HD sorbent treatment. Study Period 2: Subjects will again receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, a 2h PAK HD +/- 2h CHD therapy will be performed. Blood and dialysate samples will again be collected during treatment and sent for analysis, for comparison with the CHD therapy of the first period. After completion of study period 2 (PAK HD +/- CHD), subjects will be observed for a minimum duration of 1 h in the hospital after which they may go home if the post-dialysis period was uneventful.

06

What researchers measure

Primary outcomes

  1. The primary objective of this early feasibility clinical trial is to assess the (short term) clinical safety of the PAK HD sorbent treatment in a limited number of patients and treatments.

    The clinical safety of the PAK HD will be evaluated in terms of the following primary endpoints: 1. Absence of serious adverse events (SAE) 2. Absence of critical change in patient's clinical condition and vital parameters (Blood pressure, heart rate, body temperature and respiratory rate and pulse oximetry) during treatment. 3. Absence of critical change in haematology and biochemistry immediately before the start of therapy and immediately after completion of therapy, including acid-base state, electrolytes, and ammonia.

    Time frame: 2 weeks

Secondary outcomes

  1. The secondary objective of this study is to evaluate the efficacy of the PAK HD therapy in comparison to CHD, in terms of uremic toxin removal efficacy (urea, creatinine and phosphate).

    The therapy efficacy will be evaluated with the secondary endpoint: a) PAK HD therapy provides equivalent toxin clearances for urea, phosphate and creatinine as compared to CHD

    Time frame: 2 weeks

07

Study locations

1 site
  • National University Hospital Investigational Medicine Unit
    Singapore, 119074, Singapore
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2024, 2 months.

Of 78 industry-sponsored interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 2 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
May 29, 2024
StartActual
Feb 22, 2024
Primary completionActual
Apr 24, 2024
CompletionActual
Apr 24, 2024
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06433193
Lead sponsor
Nextkidney S.A.
Responsible party
Sponsor
First posted
May 29, 2024
Start date
Feb 22, 2024
Primary completion
Apr 24, 2024
Completion
Apr 24, 2024
Last update
Apr 1, 2025

Study contacts

Titus Wai Leong Lau, MD
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion